Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers.
Jannier S, Kemmel V, Sebastia Sancho C, Chammas A, Sabo AN, Pencreach E, Farace F, Chenard MP, Lhermitte B, Geoerger B, Aerts I, Frappaz D, Leblond P, André N, Ducassou S, Corradini N, Bertozzi AI, Guérin E, Vincent F, Velten M, Entz-Werle N. Jannier S, et al. Among authors: pencreach e. Cancers (Basel). 2020 Oct 20;12(10):3051. doi: 10.3390/cancers12103051. Cancers (Basel). 2020. PMID: 33092063 Free PMC article.
Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Pencreach E, Guérin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP, Guenot D. Pencreach E, et al. Clin Cancer Res. 2009 Feb 15;15(4):1297-307. doi: 10.1158/1078-0432.CCR-08-0889. Epub 2009 Feb 3. Clin Cancer Res. 2009. PMID: 19190131
In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis.
Guérin E, Raffelsberger W, Pencreach E, Maier A, Neuville A, Schneider A, Bachellier P, Rohr S, Petitprez A, Poch O, Moras D, Oudet P, Larsen AK, Gaub MP, Guenot D. Guérin E, et al. Among authors: pencreach e. Mol Med. 2012 Feb 10;18(1):83-94. doi: 10.2119/molmed.2011.00120. Mol Med. 2012. PMID: 22033674 Free PMC article.
Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition.
Nguyen A, Moussallieh FM, Mackay A, Cicek AE, Coca A, Chenard MP, Weingertner N, Lhermitte B, Letouzé E, Guérin E, Pencreach E, Jannier S, Guenot D, Namer IJ, Jones C, Entz-Werlé N. Nguyen A, et al. Among authors: pencreach e. Oncotarget. 2017 Mar 23;8(42):71597-71617. doi: 10.18632/oncotarget.16500. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069732 Free PMC article.
Engineering Novel 3D Models to Recreate High-Grade Osteosarcoma and its Immune and Extracellular Matrix Microenvironment.
Pierrevelcin M, Flacher V, Mueller CG, Vauchelles R, Guerin E, Lhermitte B, Pencreach E, Reisch A, Muller Q, Doumard L, Boufenghour W, Klymchenko AS, Foppolo S, Nazon C, Weingertner N, Martin S, Briandet C, Laithier V, Di Marco A, Bund L, Obrecht A, Villa P, Dontenwill M, Entz-Werlé N. Pierrevelcin M, et al. Among authors: pencreach e. Adv Healthc Mater. 2022 Oct;11(19):e2200195. doi: 10.1002/adhm.202200195. Epub 2022 Sep 4. Adv Healthc Mater. 2022. PMID: 36057996
All pineal tumors expressing germ cell tumor markers are not necessarily germ cell tumors: histopathological and molecular study of a midline primary intracranial sarcoma DICER1-mutant.
Wolf T, Coca AH, Weingertner N, Chenard MP, Meurgey A, Reita D, Pencreach E, Varlet P, Entz-Werlé N, Lhermitte B. Wolf T, et al. Among authors: pencreach e. Virchows Arch. 2023 Feb;482(2):431-435. doi: 10.1007/s00428-022-03440-2. Epub 2022 Oct 28. Virchows Arch. 2023. PMID: 36307659
36 results